⌘K
t
Beximco Pharmaceuticals Limited provided an update on the ongoing High Court hearing concerning the Bangladesh Securities and Exchange Commission's proposed appointment of nine additional independent non-executive directors. A further hearing will be held after June 21st, following its previous statement on 21 March 2025. A decision is now not expected until the end of June.
| Date | 21 May 2025 |
| Time | 15:18:26 |
| Category | Corporate updates |
| ID | 6520J |
21 May 2025
BEXIMCO PHARMACEUTICALS LIMITED
Update on BSEC Order
Beximco Pharmaceuticals Limited ("the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today provides an update on the Company's previous statement, dated 21 March 2025, on the Bangladesh Securities and Exchange Commission (BSEC)'s proposed appointment of an additional nine independent non-executive directors to the Company's Board of Directors (the "BSEC Order").
The High Court hearing is ongoing, and a further hearing shall be held after the 21 June following the planned closures of the High Court. Therefore, a decision is now not expected until the end of June. Further announcements will be made as appropriate.
For further information please visit www.beximcopharma.com or enquire to:
|
Beximco Pharma |
|
Mohammad Ali Nawaz, Chief Financial Officer Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS Executive Director & Company Secretary Tel: +880 2 41060531, Ext. 10140
|
|
SPARK Advisory Partners Limited (Nominated Adviser) Mark Brady / Andrew Emmott Tel: +44 (0)20 3368 3551 / 3555
|
|
SP Angel Corporate Finance LLP (Broker) Matthew Johnson Tel: +44 (0) 20 3470 0470
|
|
FTI Consulting Simon Conway / Sam Purewal Tel: +44 (0)20 3727 1000
|
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.